SML1088
SRPIN340
≥98% (HPLC)
別名:
(SRPIN)340, N-[2-(1-Piperidinyl)-5-(trifluoromethyl)phenyl]-4-pyridinecarboxamide
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C18H18F3N3O
CAS番号:
分子量:
349.35
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51111800
MDL number:
InChI
1S/C18H18F3N3O/c19-18(20,21)14-4-5-16(24-10-2-1-3-11-24)15(12-14)23-17(25)13-6-8-22-9-7-13/h4-9,12H,1-3,10-11H2,(H,23,25)
SMILES string
O=C(C1=CC=NC=C1)NC2=C(N3CCCCC3)C=CC(C(F)(F)F)=C2
InChI key
DWFGGOFPIISJIT-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 20 mg/mL, clear
storage temp.
2-8°C
Quality Level
関連するカテゴリー
Application
SRPIN340 has been used as a serine-arginine protein kinase (SRPK) inhibitor to identify if SRPK can phosphorylate the E3 ubiquitin ligase RNF12 ser/arg (SR)-motifs in vivo.
Biochem/physiol Actions
SRPIN340 is a cell-permeable, specific and potent inhibitor of Serine-Arginine-Rich Protein Kinase (SRPK) that down-regulates SRp75 and inhibits expression of Sindbis, hepatitis C virus (HCV), HIV, and cytomegalovirus viruses. SRPIN340 appears to be most effective for inhibiting acutely replicating viruses. SRPIN340 suppresses Vegf expression and attenuated choroidal neovascularization (CNV) formation in mice model.
SRPIN340 is a cell-permeable, specific and potent inhibitor of Serine-Arginine-Rich Protein Kinase (SRPK).
SRPIN340 is an isonicotinamide compound. It protects cardiomyocytes against hydrogen peroxide (H2O2) induced oxidative damage by serine-arginine protein kinase 1/2 (SRPK1/2) inhibition-mediated protein kinase B (AKT) activation.
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
SML1088-25MG: + SML1088-5MG: + SML1088-VAR: + SML1088-BULK:
jan
SRPIN340 protects heart muscle from oxidative damage via SRPK1/2 inhibition-mediated AKT activation.
Jian Huang et al.
Biochemical and biophysical research communications, 510(1), 97-103 (2019-01-22)
SRPIN340, a selective serine-arginine protein kinase 1/2 (SRPK1/2) inhibitor, has been shown to have antiviral and anti-angiogenesis effects. However, its role in the heart is unknown. The present study explored the role of SRPIN340 in myocardial protection and the related
Zhenyu Dong et al.
Molecular vision, 19, 536-543 (2013-04-06)
To investigate the applicability of serine/arginine-rich protein kinase (SRPK)-specific inhibitor, SRPIN340, for attenuation of choroidal neovascularization (CNV) formation using a mouse model. Laser photocoagulation was performed to induce CNV in C57BL/6J mice, followed by intravitreal injection of SRPIN340 or vehicle.
Parmanand Malvi et al.
Oncogenesis, 9(8), 77-77 (2020-08-30)
Triple-negative breast cancer (TNBC) is a highly metastatic breast cancer subtype and due to the lack of hormone receptors and HER2 expression, TNBC has limited therapeutic options with chemotherapy being the primary choice for systemic therapy. LIM Domain Kinase 2
Richard P Hulse et al.
Neurobiology of disease, 96, 186-200 (2016-10-19)
Neuropathic pain results from neuroplasticity in nociceptive neuronal networks. Here we demonstrate that control of alternative pre-mRNA splicing, through the splice factor serine-arginine splice factor 1 (SRSF1), is integral to the processing of nociceptive information in the spinal cord. Neuropathic
Gabriela Alves Moreira et al.
Toxicology and applied pharmacology, 356, 214-223 (2018-08-24)
The Serine/arginine-rich protein kinases (SRPK) are involved in pre-mRNA splicing control through the phosphorylation of the SR protein family of splicing factors. Over the last years, several studies have shown the relevance of SRPK for human cancers and their potential
資料
Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）